Sandoz, a Novartis division focused on biosimilars, announced that it will not pursue its submission for biosimilar rituximab in the US at this time.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
